How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

482 results for

Seasonal Oral Contraceptive Cycle

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Seasonal Oral Contraceptive Cycle

Seasonal Oral Contraceptive Cycle Seasonal Oral Contraceptive Cycle Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Seasonal Oral (...) Contraceptive Cycle Seasonal Oral Contraceptive Cycle Aka: Seasonal Oral Contraceptive Cycle , Extended-Cycle Oral Contraceptive , Seasonale , Lybrel , LoSeasonique , Quartette II. Indications Heavy Women wanting to reduce to 4 times per year III. Techique: Seasonal, 84 day regimen Continue active pills (no pills) until: Breakthrough bleeding or 84 days pass When active phase completed Hormone free: 5-7 days IV. Preparations Any monophasic may be used Simply do not take pills Much less expensive

2018 FP Notebook

2. Oral Contraceptive

Contraceptive , Birth Control Pill II. Epidemiology United States: 18 million users Average length of use: 4.8 months Efficacy Typical use: 3-5% failure rate Perfect use: 0.1% failure rate III. Benefits Long Term benefits risk decreased (30-50% reduction) risk decreased (30-50% reduction) Fibrocystic disease decreased Acute risk decreased Effects Increased regularity Decreased blood loss Decreased of risk reduced Inhibition effects Decreased functional s Decreased IV. Precautions: Risks associated with Oral (...) Effects (10% new ) abnormalities (lowers HDL-2) Adverse effects not associated with Oral Contraceptives Weight gain is not significant Hordinsky (2000) Eighth World Congress Int Gyn Endo VIII. Preparations: Combined Contraceptive Formulations Monophasic Triphasic Triphasic s (20-35 ug) IX. Preparations: Cycle Types Standard: 21 days hormonal, 7 days hormone free Extended: 24 day regimen, 4 days hormone free Seasonal: 84 day regimen, 5-7 days hormone free See X. Efficacy High failure rate with P450

2018 FP Notebook

3. Oral Contraceptive-Related Uterine Bleeding Management

at beginning of next cycle VIII. References Dickey (1998) Managing Contraceptive Pill Patients Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Oral Contraceptive-Related Uterine Bleeding Management." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Pharmacology About FPnotebook.com is a rapid access, point-of-care medical reference for primary (...) Oral Contraceptive-Related Uterine Bleeding Management Oral Contraceptive-Related Uterine Bleeding Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse

2018 FP Notebook

4. Oral Contraceptive Side Effect Management

Oral Contraceptive Side Effect Management Oral Contraceptive Side Effect Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Oral Contraceptive Side Effect Management Oral Contraceptive Side Effect Management Aka: Oral Contraceptive Side Effect Management II. Management: Nausea Take pill at bedtime, or at a meal Use Low pill (e.g. ) III. Management: Fluid Retention Change to OCP with the following characteristics Low (or low dose) Examples IV. Management: Appetite too active or weight gain Change to OCP with the following characteristics Low (or low dose) Low Examples V. Management: Hypertension Discontinue Consider

2018 FP Notebook

5. Seasonal Oral Contraceptive Cycle

Seasonal Oral Contraceptive Cycle Seasonal Oral Contraceptive Cycle Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Seasonal Oral (...) Contraceptive Cycle Seasonal Oral Contraceptive Cycle Aka: Seasonal Oral Contraceptive Cycle , Extended-Cycle Oral Contraceptive , Seasonale , Lybrel , LoSeasonique , Quartette II. Indications Heavy Women wanting to reduce to 4 times per year III. Techique: Seasonal, 84 day regimen Continue active pills (no pills) until: Breakthrough bleeding or 84 days pass When active phase completed Hormone free: 5-7 days IV. Preparations Any monophasic may be used Simply do not take pills Much less expensive

2015 FP Notebook

6. Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

are dependent on the route of administration such that an attenuation of these effects is observed when a comparable dose of non-oral transdermal contraceptive (TDC) therapy and contraceptive vaginal ring (CVR) therapy are also tested. Millions of women use COC therapy for birth control purposes or regulation of menstrual cycles. TDC and CVR therapies are relatively new FDA-approved contraceptive alternatives to COC. The purpose of the proposed project is to address the potential mechanism(s) by which oral (...) -term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of combined oral contraceptive (Apri or Reclipsen) on the GH/IGF-1 axis. Other Name: Apri (Reclipsen) Experimental: Transdermal Contraceptive (TDC) Participants in the TDC group will apply a 20 cm2 patch (Xulane: 20µg/d EE,150µg/d norelgestromin) to the abdomen, upper arm or buttock. The patch will be changed once weekly

2015 Clinical Trials

7. Assessing the Impact of Contraceptives on Bone Health Using 41Ca

contraceptive (COC) therapy on bone turnover are dependent on the route of administration such that an attenuation of these effects is observed when a comparable dose of non-oral contraceptive therapy, such as vaginal contraceptive (CVR) therapy is also tested. Millions of women use COC therapy for birth control purposes or regulation of menstrual cycles. CVR therapy is a relatively new FDA-approved contraceptive alternative to COC. The purpose of the proposed project is to investigate whether oral ethinyl (...) of markers of bone formation and bone resorption [ Time Frame: 49 days of contraceptive therapy ] Changes in fasting serum concentrations of markers of bone formation (osteocalcin, P1NP) and bone resorption (CTx) after oral and non-oral contraceptive therapy Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about

2015 Clinical Trials

8. Oral Contraceptive-Related Uterine Bleeding Management

at beginning of next cycle VIII. References Dickey (1998) Managing Contraceptive Pill Patients Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Oral Contraceptive-Related Uterine Bleeding Management." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Pharmacology About FPnotebook.com is a rapid access, point-of-care medical reference for primary (...) Oral Contraceptive-Related Uterine Bleeding Management Oral Contraceptive-Related Uterine Bleeding Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse

2015 FP Notebook

9. Oral Contraceptive Side Effect Management

Oral Contraceptive Side Effect Management Oral Contraceptive Side Effect Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Oral Contraceptive Side Effect Management Oral Contraceptive Side Effect Management Aka: Oral Contraceptive Side Effect Management II. Management: Nausea Take pill at bedtime, or at a meal Use Low pill (e.g. ) III. Management: Fluid Retention Change to OCP with the following characteristics Low (or low dose) Examples IV. Management: Appetite too active or weight gain Change to OCP with the following characteristics Low (or low dose) Low Examples V. Management: Hypertension Discontinue Consider

2015 FP Notebook

10. Oral Contraceptive

Contraceptive , Birth Control Pill II. Epidemiology United States: 18 million users Average length of use: 4.8 months Efficacy Typical use: 3-5% failure rate Perfect use: 0.1% failure rate III. Benefits Long Term benefits risk decreased (30-50% reduction) risk decreased (30-50% reduction) Fibrocystic disease decreased Acute risk decreased Effects Increased regularity Decreased blood loss Decreased of risk reduced Inhibition effects Decreased functional s Decreased IV. Precautions: Risks associated with Oral (...) Effects (10% new ) abnormalities (lowers HDL-2) Adverse effects not associated with Oral Contraceptives Weight gain is not significant Hordinsky (2000) Eighth World Congress Int Gyn Endo VIII. Preparations: Combined Contraceptive Formulations Monophasic Triphasic Triphasic s (20-35 ug) IX. Preparations: Cycle Types Standard: 21 days hormonal, 7 days hormone free Extended: 24 day regimen, 4 days hormone free Seasonal: 84 day regimen, 5-7 days hormone free See X. Efficacy High failure rate with P450

2015 FP Notebook

11. Palliative care - oral

mouth. Regular mouth care to prevent oral problems is standard nursing practice [ ] and is based on expert opinion [ ; ] and local guidelines [ ]: A small prospective study (n = 42) of children 6 to 17 years of age with haematological cancers or solid tumours compared an oral care protocol intervention (tooth brushing, 0.2% chlorhexidine mouth rinse, 0.9% saline rinse) (n = 21) with no intervention (n = 21) [ ]. Compared with the control group, the protocol intervention group had: A reduction (...) Palliative care - oral Palliative care - oral - NICE CKS Share Palliative care - oral: Summary Common oral problems in palliative care include dry mouth, painful mouth, halitosis, alteration of taste, and excessive salivation. They may result from poor oral intake, drug treatments, local irradiation, oral tumours, or chemotherapy. Oral symptoms may significantly affect the person's quality of life, causing eating, drinking, and communication problems, and oral discomfort and pain. When

2018 NICE Clinical Knowledge Summaries

12. Oral Melatonin as Premedication During MAC for Patients Undergoing Loco-regional Chronic Subdural Hematoma Evacuation

(Clinical Trial) Actual Enrollment : 40 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: (N-acetyl-5-methoxytryptamine) is a neurohormone secreted by the pineal gland. It is primarily responsible for the sleep awake cycle as its level decreases in the morning and increases by night; owing to reduced light intensity, leading to circadian rhythm. It provides circadian and seasonal timing through activation of G protein-coupled receptors (GPCRs (...) to the start of the study, the appropriately numbered envelopes will be opened by the nurse, the card will determine the assigned intervention for each patient, which will be prepared by a clinical pharmacist with no other role in the study Primary Purpose: Supportive Care Official Title: Oral Melatonin as Premedication During Monitored Anaesthesia Care for Patients Undergoing Loco-regional Chronic Subdural Hematoma Evacuation, a Randomized Controlled Trial Actual Study Start Date : September 5, 2018

2018 Clinical Trials

13. A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers

the flu season, which is allowed 7 days before or after dosing Note 2: Allowed medications include: oral contraceptives; H1 antihistamines; topical/ intranasal corticosteroids; nonsteroidal anti-inflammatory drugs [NSAIDS]; licensed influenza vaccine during the flu season, 7 days before or after dosing. 14) Use of any non-prescription medication, herbal preparation, or nutritional supplement within 15 days before dosing or planned use during the study unless approved by the study clinician Note (...) on becoming pregnant during the trial and for 30 days after study participation Females of childbearing potential and males agree to use acceptable contraception for the duration of the trial and for 30 days (females) or 90 days (males) after final study visit - Note: A highly effective method of birth control is defined as one with a low failure rate (i.e., less than 1 percent per year) according to the CDC criteria. These include progestin implants, intrauterine devices (IUDs), surgical (hysterectomy

2018 Clinical Trials

14. Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias

: January 28, 2019 See Sponsor: M.D. Anderson Cancer Center Collaborator: Merck Sharp & Dohme Corp. Information provided by (Responsible Party): M.D. Anderson Cancer Center Study Details Study Description Go to Brief Summary: The goal of this clinical research study is to compare pembrolizumab to standard of care observation (no treatment) in controlling oral pre-malignant lesions and IENs. The safety and tolerability of pembrolizumab will also be studied. This is an investigational study. Pembrolizumab (...) levels > 1.5 ULN. AST (SGOT) and ALT (SGPT) birth control or be surgically sterile, or abstain from heterosexual activity for the course of study

2016 Clinical Trials

15. Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy Volunteers

using hormonal contraceptives must also be using an additional approved method of contraception (as described previously) starting at Cycle 1 Day 1, and continuing throughout the entire study period and for 2 months after the last dose of study drug. Postmenopausal women must have been amenorrheic for at least 12 consecutive months; otherwise a pregnancy test is required. Male patients must agree to use contraceptive methods (eg, abstinence, condom + spermicide or a double-barrier method [eg, condom (...) Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy Volunteers Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2015 Clinical Trials

16. A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers

a negative serum and urine B-hCG test result at Screening and Baseline. Females of child-bearing potential must agree to use a medically acceptable method of contraception (e.g., abstinence; a highly effective method such as an intrauterine device [IUD], condom + spermicide or condom + diaphragm with spermicide, a contraceptive implant, an oral contraceptive; or have a vasectomized partner) throughout the entire study period and for 30 days after study drug discontinuation. The only subjects who (...) cycle prior to starting study drug(s) and throughout the entire study and for 30 days after the last dose of study drug. Those with partners using hormonal contraceptives must also be using an additional approved method of contraception (as described previously). Provide written informed consent Are willing and able to comply with all aspects of the protocol Exclusion Criteria Subjects who had a clinically significant illness that required medical treatment within 8 weeks or a clinically significant

2014 Clinical Trials

17. 30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder

within the previous 6 months or any history of goLITE use Pregnant or lactating (will confirm absence of pregnancy with a urine or serum pregnancy test in females of childbearing potential during the Physical Screening. Additional pregnancy tests may be performed as per individual site requirements). Females of child-bearing potential must agree to use some form of birth control throughout the course Current use or use within 2 months of antidepressants or mood stabilizing medications, even if taken (...) for a non-psychiatric indication Currently working night shift or rotating shift or other habitual alteration of the sleep/wake cycle Planned travel outside of the state in which the trial is being conducted Current use or use within the previous 1 month of photosensitizing medications (amiodarone, benoxaprofen, chlorpromazine, demeclocycline, fleroxacin, nalidixic acid, ofloxacin, piroxicam, porfimer, psoralens, quinidine, temoporfin) or remedies (St. John's wort, melatonin) History of eye trauma

2011 Clinical Trials

18. Flu vaccination: increasing uptake

, and community and voluntary sector organisations that employ health and social care workers Occupational health services and infection prevention and control teams NHS England teams and Health Education England teams People using services, their families, carers and other members of the public, in particular those eligible for flu vaccination Flu vaccination: increasing uptake (NG103) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice (...) vaccination. 1.5.4 Use audit and monitoring systems to give providers of flu vaccination regular feedback on organisational progress towards targets throughout the immunisation season. Also use them to review past activity and impact on uptake to help plan and prioritise for the next season. Organisational incentiv Organisational incentives es 1.5.5 Commissioners should raise awareness among healthcare staff and providers of flu vaccination about enhanced services payments and provider payments Flu

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

19. Chronic obstructive pulmonary disease in over 16s: diagnosis and management

, in consultation with them and their families and carers or guardian. Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health (...) 53 Oral prophylactic antibiotic therapy 54 Long-term oxygen therapy 55 Ambulatory and short-burst oxygen therapy 56 Managing pulmonary hypertension and cor pulmonale 57 Lung volume reduction procedures, bullectomy and lung transplantation 58 Risk factors for COPD exacerbations 59 Self-management, education and telehealth monitoring 60 Context 62 Finding more information and resources 63 Update information 64 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115) ©

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

20. Clinical care of severe acute respiratory infections – Tool kit

algorithm for patient presenting with acute respiratory infection (influenza or COVID-19 suspected or known to be circulating) 28 2.7 Decision-making algorithm for hospitalization of patient with pneumonia (influenza or COVID-19 known to be circulating) 30 2.8 Decision-making support tool for hospitalization and ICU admission for patient with severe acute respiratory infection and severe pneumonia 32 2.9 Checklist for admission 33 2.10 Checklist for transfer 34 3. INFECTION PREVENTION AND CONTROL (...) FOR PATIENTS WITH SARI 35 Summary 36 References and resources 37 3.1 How to implement infection control measures for COVID-19 38 3.2 How to implement infection control measures for SARI 39 3.3 Personal protective equipment (PPE) 40 3.4 Hand hygiene 42 3.5 Checklist for aerosol-generating procedures 43 iii Contents 4. MONITORING THE PATIENT 45 Summary 46 References and resources 47 4.1 AVPU scale: a simple tool for assessing level of consciousness 49 4.2 Pulse oximetry monitoring 50 4.3 Blood gas analysis

2020 WHO Coronavirus disease (COVID-19) Pandemic

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>